The Blood Screening Market is becoming increasingly important as healthcare systems focus on maintaining the safety and quality of donated blood. Blood screening involves testing donated blood for transfusion-transmissible infections and other risks before blood products are released for clinical use. Growing blood donation volumes, increasing awareness of transfusion safety, and the continuing need to identify infectious diseases are supporting demand for advanced screening technologies. According to a recent report by Market Research Future, the global market was valued at USD 3.46 billion in 2025 and is projected to reach USD 8.19 billion by 2035, expanding at a 9.0% CAGR from 2026 to 2035. Modern screening technologies include nucleic acid amplification testing, enzyme-linked immunosorbent assays, and next-generation sequencing. These approaches can help laboratories detect pathogens and other markers with greater efficiency. Automation is also becoming an important part of blood screening because centralized systems can process large numbers of samples while reducing manual intervention. The increasing adoption of automated and integrated platforms is helping blood centers improve workflow and standardize testing procedures. Market Growth is also being supported by stricter regulatory expectations surrounding donor assessment and transfusion safety. Blood banks and clinical laboratories are therefore investing in equipment, reagents, software, and integrated diagnostic platforms. However, high equipment costs, complex regulatory requirements, skilled workforce needs, and the necessity for reliable laboratory infrastructure can create challenges for some organizations.

The future of the Blood Screening Market is expected to be shaped by molecular diagnostics, automation, artificial intelligence, pathogen-reduction technologies, and integrated laboratory platforms. Molecular screening can provide opportunities to identify infections during periods when conventional methods may have limitations. AI-powered systems could support data interpretation, quality control, and inventory management, while automated platforms can improve throughput in high-volume blood centers. Market Trends are also moving toward multiplex testing, allowing multiple pathogens or markers to be assessed through increasingly streamlined workflows. North America currently represents a significant regional market, while Asia-Pacific is expected to demonstrate strong expansion as blood-banking infrastructure and screening capabilities continue to develop. Emerging markets may benefit from point-of-care molecular screening technologies that can support remote collection locations. Increasing adoption of digital laboratory systems could also improve traceability and result management. As healthcare providers and blood organizations continue prioritizing patient safety, demand for accurate, rapid, and scalable screening solutions is likely to increase. Market Forecast expectations remain favorable, with continued technological development creating opportunities for manufacturers of instruments, reagents, testing platforms, and laboratory software. The long-term evolution of the industry will depend on combining reliable diagnostics with automation, affordability, regulatory compliance, and efficient blood-management practices.